###begin article-title 0
Plasma Interleukin-18 and Dendritic Cells in Males with Psoriasis Vulgaris
###end article-title 0
###begin p 1
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 573 580 <span type="species:ncbi:9606">patient</span>
###xml 623 630 <span type="species:ncbi:9606">patient</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
Peripheral blood dendritic cells seem to play a crucial role in psoriatic inflammatory processes. The aim of our study is to investigate the relationship between plasma interleukin-18 (IL-18) levels and blood dendritic cells in psoriatic patients. IL-18 plasma levels were measured by ELISA. Phenotypes of dendritic cell subsets were analyzed by double-colour flow cytometry. Plasma IL-18 level in psoriatic males was significantly higher, whereas counts of BDCA-2+ cells were lower than in the control group. The myeloid/plasmacytoid ratio was significantly higher in the patient group compared to the control one. In the patient group, significant negative correlations between plasma IL-18 level and both the BDCA-1+ and BDCA-2+ counts were found. BDCA-1+ counts correlated negatively with percentage of skin involvement. IL-18 seems to play a role in psoriasis pathogenesis. The decreased counts of blood plasmacytoid DCs in psoriatic patients might result from IL-18 down-regulation of plasmacytoid DC precursor proliferation.
###end p 2
###begin title 3
1. INTRODUCTION
###end title 3
###begin p 4
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 523 528 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 534 539 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 696 697 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 698 699 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
Interleukin-18 (IL-18) is produced by a wide range of cells, primarily macrophages, monocytes, and to a smaller degree by keratinocytes and osteoblasts [1]. It strengthens cytotoxic properties of natural killer (NK) cells and CD8+ T cells. It also possesses a unique ability to increase the activity of both Th1-type as well as Th2-type CD4+ T cells and depends on local cytokine network [2]. IL-18 contributes to inflammation and fever due to its potent inducing effects on the gene expression and synthesis of interferon-gamma (IFN-gamma), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF), interleukin-1 (IL-1), fas ligand (FasL), and several chemokines [3-7]. Being a pleiotropic cytokine, IL-18 can play an immunoregulatory role, especially in inflammatory, infectious, and autoimmune diseases.
###end p 4
###begin p 5
###xml 69 70 69 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 344 349 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 466 468 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 872 874 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 875 877 871 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 648 656 <span type="species:ncbi:9606">patients</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
Only a few studies analysed the role of IL-18 in psoriasis vulgaris [4, 8-10], they did not, however, yield conclusive results [11]. Increased expression of IL-18 was demonstrated in keratinocytes from psoriatic lesions in comparison to keratinocytes from normal skin [12-15]. However, neither the bioactivity of IL-18 nor the influence of IFN-gamma on inflammatory processes in the peripheral blood mononuclear cells (PBMC) from psoriatic scales could be detected [12]. The level of IL-18 mRNA was demonstrated to be 2- to 8-fold higher in extracts from psoriatic skin lesions than the one obtained from both uninvolved skin extracts in psoriasis patients and healthy subjects. Similarly, 6- to 8-fold higher concentrations of IL-18 receptors mRNA were observed in psoriatic lesional skin in comparison to both uninvolved skin of psoriasis patients and healthy subjects [13-15].
###end p 5
###begin p 6
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 7 12 <span type="species:ncbi:9606">human</span>
In the human peripheral blood, two distinct lineages of dendritic cells (DCs) were identified-myeloid and plasmacytoid dendritic cells (mDCs and pDCs, resp.) [16]. These two subsets of DCs have been implicated in inducing diverse types of immune responses, with mDCs favouring Th1- and pDCs favouring Th2-type immune reactions profile [17]. These two DCs subsets can be distinguished by their different surface antigens. mDCs express specific antigen-blood dendritic cell antigen BDCA-1, whereas pDCs express characteristic antigen BDCA-2 [18].
###end p 6
###begin p 7
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 644 646 644 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
Recent data indicate that DCs may be involved in pathological processes in numerous diseases, including immune-mediated skin conditions [19, 20]. In psoriasis, BDCA-2 cells were detected in the basal layer of the epidermis and the papillary dermis [20]. This observation is particularly interesting in the context of the most important immunopathogenic hypotheses of psoriasis focused on the synthesis and release of proinflammatory mediators by activated DCs and T cells, distorted function of the immune synapse leading to the emergence of self-reactive T cells or epidermal expression of chemokines attracting T cells and DCs into the skin [21].
###end p 7
###begin p 8
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Some studies suggested that DCs may be associated with IL-18. Gutzmer et al. [22] have recently demonstrated that human DCs express IL-18 receptors and that IL-18 has a direct chemotactic effect on DCs. Increased IL-18 levels, observed in some diseases, might lead to DCs recruitment to the sites of inflammation. Companjen et al. [11] found that in the epidermis, IL-18 expression was detected not only in keratinocytes but also in the cells with a dendritic morphology, probably Langerhans cells. The cellular infiltrate in the dermal papillae of psoriatic lesional skin, containing cells with dendritic and lymphocyte morphology, also expressed IL-18.
###end p 8
###begin p 9
###xml 211 219 <span type="species:ncbi:9606">patients</span>
Since several lines of evidence link the pathogenesis of psoriasis to both increased levels of IL-18 and DCs functions, we decided to investigate the relationship between plasma IL-18 and blood DCs in psoriasis patients. We hypothesized that such correlation may help to explain some of the pathogenic processes observed in the psoriatic skin.
###end p 9
###begin title 10
2. MATERIALS AND METHODS
###end title 10
###begin title 11
###xml 5 17 <span type="species:ncbi:9606">Participants</span>
2.1. Participants
###end title 11
###begin p 12
###xml 89 97 <span type="species:ncbi:9606">Patients</span>
###xml 250 258 <span type="species:ncbi:9606">Patients</span>
###xml 519 526 <span type="species:ncbi:9606">patient</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
###xml 959 971 <span type="species:ncbi:9606">participants</span>
###xml 992 1000 <span type="species:ncbi:9606">patients</span>
###xml 1159 1170 <span type="species:ncbi:9606">participant</span>
Thirty-eight males with psoriasis and 21 healthy male volunteers took part in the study. Patients were hospitalized at Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Poland, due to psoriasis vulgaris. Patients had a chronic active type of psoriasis of moderate severity with the mean psoriasis area and severity index (PASI) of 24.56 +/- 8.28 (M +/- SD) and the average percentage of skin involvement of 28.44 +/- 19.54%. The severity of psoriasis was evaluated in each patient by the same investigator. The mean duration of psoriasis calculated in months was 152.10 +/- 149.46. The patients treated with topical or systemic steroids, any form of dithranol or retinoid therapy prior to examination, were excluded from entering the study. Subjects with other systemic, infectious, parasitic, neurological, or psychiatric diseases were also excluded from the study. The blood samples were collected from all the participants in the morning. The patients remained seated for at least 15 minutes prior to blood collection. An informed written consent was obtained after complete description of the study from each participant. The study was approved by the Ethics Committee of the Medical University of Lublin.
###end p 12
###begin title 13
2.2. Evaluation of DCs subpopulations
###end title 13
###begin p 14
###xml 182 184 182 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 180 184 180 184 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ca<sup>2+</sup></chem-struct>
###xml 191 193 191 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 189 193 189 193 <chem-struct xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Mg<sup>2+</sup></chem-struct>
###xml 1142 1150 1142 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 210 216 <span type="species:ncbi:9913">bovine</span>
###xml 345 350 <span type="species:ncbi:10090">mouse</span>
The mononuclear cells were isolated from heparinised blood by density gradient centrifugation on Lymphoprep (Nycomed, Norway) and washed twice in phosphate buffered saline without Ca2+ and Mg2+ containing 0.5% bovine serum albumin and 2 mM EDTA. The phenotypes of DCs were analysed with double-colour flow cytometry using monoclonal antibodies: mouse antihuman BDCA-1-FITC (Miltenyi-Biotec, Germany), CD19-CyChrome (Pharmingen, USA), BDCA-2-FITC (Miltenyi-Biotec, Germany), CD123-PE (Becton Dickinson, USA), and matched isotype control (Caltag, USA). The cell staining was performed according to the manufacturers' instructions in the presence of FcR blocking reagent (Miltenyi-Biotec, Germany). The immunolabelled cells were collected (a total of 300 000 events) using an FACSCalibur flow cytometer equipped with 488 nm argon laser (Becton Dickinson) and analysed with cell-quest software. The numbers of myeloid and plasmacytoid DCs were quantified as the percentages of peripheral blood mononuclear cells. mDCs were defined as BDCA-1 positive and simultaneously CD19 negative cells, whereas pDCs as double BDCA-2 and CD123 positive cells (Figure 1).
###end p 14
###begin title 15
2.3. Evaluation of IL-18 plasma concentration
###end title 15
###begin p 16
###xml 70 75 <span type="species:ncbi:9606">Human</span>
###xml 405 410 <span type="species:ncbi:9606">Human</span>
Plasma IL-18 concentration was determined by a commercially available Human IL-18 ELISA kit (MBL, Japan). Plasma samples were collected on EDTA as anticoagulant and stored deep frozen at -80degreesC until further evaluated. The analytical procedure was performed according to the manufacturers' instructions. ELISA Reader Elx800 (BIO-TECK Instruments) was used for the examination. The detection limit of Human IL-18 ELISA kit is 12.5 pg/mL.
###end p 16
###begin title 17
3. STATISTICAL ANALYSIS
###end title 17
###begin p 18
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">U</italic>
###xml 412 415 412 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 492 493 492 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 371 378 <span type="species:ncbi:9606">patient</span>
Results are presented as mean, median, 25 percentile and 75 percentile, mean (M), standard deviation (SD). The fit of the data to the normal distribution was tested with Kolmogorov-Smirnov test. Since the distribution of the data was significantly different from normal, nonparametric statistics were further used. Mann-Whitney U test was employed for comparison between patient and control groups, and Spearman rho correlations coefficients were calculated between the assessed variables. A P value <.05 was considered statistically significant.
###end p 18
###begin title 19
4. RESULTS
###end title 19
###begin title 20
4.1. Group characteristics
###end title 20
###begin p 21
###xml 256 263 256 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 410 411 410 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
The patients and healthy controls were homogeneous with respect to the number of demographic, physical, and behavioural variables including age, weight, height, body mass index (BMI), blood pressure, WBC, frequency of smoking, and declared alcohol intake (Table 1). None of the differences between the patients and healthy subjects in the mean values of these variables proved to be statistically significant (P < .05).
###end p 21
###begin title 22
###xml 36 44 <span type="species:ncbi:9606">patients</span>
4.2. IL-18 levels and DCs counts in patients and healthy subjects
###end title 22
###begin p 23
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 256 257 256 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 510 518 510 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 334 342 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
The mean plasma level of IL-18 was significantly increased in males with psoriasis as compared to the healthy control male group (P = .027). The counts of BDCA-1+ cells in psoriasis patients were not significantly different from those in healthy controls (P < .05). The counts of BDCA-2+ cells were found to be significantly lower in patients with psoriasis than those in healthy controls (P = .001). The myeloid/plasmacytoid ratio was significantly higher in psoriatic patients compared to the control group (Figure 2).
###end p 23
###begin title 24
###xml 43 51 <span type="species:ncbi:9606">patients</span>
4.3. Correlations between IL-18 and DCs in patients and healthy subjects
###end title 24
###begin p 25
###xml 378 381 378 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 450 453 450 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 464 471 464 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 473 481 473 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 100 107 <span type="species:ncbi:9606">patient</span>
###xml 234 241 <span type="species:ncbi:9606">patient</span>
In the correlations between IL-18 and BDCA-1+ cells, BDCA-2+ cells were examined separately for the patient and the control groups. In the latter, none of the correlation coefficients was found to be statistically significant. In the patient group, however, statistically significant negative correlations were found both between the BDCA-1+ cell counts and plasma IL-18 level (rho = -0.38) as well as the BDCA-2+ cell counts and plasma IL-18 level (rho = -0.41) (Table 2, Figure 3).
###end p 25
###begin title 26
###xml 73 81 <span type="species:ncbi:9606">patients</span>
4.4. Correlations between IL-18, DCs, and clinical severity of psoriasis patients
###end title 26
###begin p 27
###xml 537 540 537 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 551 558 551 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 7 14 <span type="species:ncbi:9606">patient</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
In the patient group, correlation coefficients were calculated between the DCs subpopulations, IL-18, and clinical severity of the disease. Neither DCs nor IL-18 showed statistically significant correlations with the severity of psoriasis expressed by PASI score. IL-18 and BDCA-2+ did not demonstrate statistically significant correlations with percentage of skin involvement in psoriatic patients either. However, the severity of the disease, expressed by percentage of skin involvement correlated negatively with BDCA-1+ cell counts (rho = -0.39) (Table 3).
###end p 27
###begin title 28
5. DISCUSSION
###end title 28
###begin p 29
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 344 349 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 456 458 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 460 462 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 771 773 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 909 914 905 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 999 1001 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1003 1005 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
Our patients with psoriasis showed significantly increased levels of plasma IL-18 as compared to healthy subjects, which confirms findings reported by other authors [4], and our previous ones [8-10]. Increased IL-18 levels found in our patients seem to be in agreement with the widely accepted observation that IL-18 is a potent inducer of IFN-gamma from T cells, NK cells, B cells, dendritic cells and, generally, is a trigger of the Th1 immune response [11, 23]. Taking into account the fact that psoriasis is a Th1-type disease, IL-18 may be regarded to be of some importance in its pathogenesis. This is further supported by studies demonstrating decrease of IL-18 levels after narrowband UVB therapy together with other parameters' characteristics for Th1 response [24]. Apart from stimulating the Th1 response, IL-18 can regulate the Th2 response depending on local cytokine network. IL-12 enhances IFN-gamma production induced by IL-18, whereas IL-18 alone induces IL-4 and IL-13 production [23, 25].
###end p 29
###begin p 30
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 274 279 274 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 311 316 307 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 479 484 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 565 567 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 569 571 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 944 952 932 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1106 1108 1094 1096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1235 1240 1223 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 1286 1288 1270 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 781 789 <span type="species:ncbi:9606">patients</span>
These unique properties of IL-18 could explain statistically significant negative correlations between the BDCA-1+ cell counts and plasma IL-18 level as well as the BDCA-2+ cell counts and plasma IL-18 level. Kaser et al. [26] showed that plasmacytoid DC lineage express an alpha chain of IL-18 receptor (IL-18Ralpha). Therefore, IL-18 can directly down-regulate proliferation of plasmacytoid DC precursors (pre-DC2s). This, in turn, can lead to a decrease in BDCA-2+ cells. IFN-gamma was demonstrated to up-regulate the IL-18R on monocyte-derived dendritic cells [22, 27]. It might have the similar effect on dendritic cells in vivo. Our results show the statistically significant decrease of BDCA-2+ cells and the significantly higher myeloid/plasmacytoid ratio in the psoriatic patients compared to the control group. Spearman's rank correlation coefficients indicated that negative correlation between IL-18 and BDCA-2+ is more pronounced (Figure 3). This finding could be explained by both the direct influence of IL-18 on plasmacytoid DCs, which in psoriasis is enhanced by increased level of IL-12 [24], as well as additional function of IL-4. The Th2-type cytokine-IL-4 is able to induce apoptosis of plasmacytoid DCs, but IFN-gamma can protect BDCA-2+ cells from this process [28].
###end p 30
###begin p 31
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
Nestle et al. [29] observed a lower level of BDCA-2+ cells in the blood of psoriatic patients than in healthy subjects. They suggested that BDCA-2+ cells are decreased in the blood of psoriatic patients due to their migration into the lesional skin, a phenomenon similar to that observed in systemic lupus erythematosus. Therefore, the decreased counts of BDCA-2+ cells we found in our patients might possibly be related to their presumed migration into the lesional skin. This remains in agreement with the findings of other authors who observed increased DCs counts in the lesional psoriatic skin [20, 29].
###end p 31
###begin p 32
###xml 15 17 15 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
###xml 743 751 <span type="species:ncbi:9606">patients</span>
Nestle et al. [29] found an elevated level of plasmacytoid DCs in both plaque lesions and uninvolved skin of psoriatic patients as compared to the skin of control subjects. Kaser et al. [26] analysed the role of IL-18 in the initial phase of Th response and demonstrated that IL-18 interacts with the differentiation pathway of plasmacytoid DCs. Through this modulation, IL-18 shifts the Th1/Th2 balance towards Th1 response. The potent chemotactic activity of IL-18 on plasmacytoid DCs was also identified. Further studies are, however, required to examine the chemotactic effect of IL-18 on plasmacytoid DCs in the psoriatic patients' skin and blood. What is more is that investigation on the expression of IL-18R on plasmacytoid DCs in the patients' skin and blood seems to be of considerable usefulness.
###end p 32
###begin p 33
###xml 199 202 199 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 384 389 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 455 457 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 804 809 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
###xml 701 709 <span type="species:ncbi:9606">patients</span>
The counts of BDCA-1+ cells were not significantly different in the blood of our psoriatic patients from that of healthy controls. However, our study demonstrated a significant negative correlation (rho = -0.38) between plasma IL-18 and BDCA-1+ cell counts in patients with psoriasis. This negative correlation may be the result of myeloid dendritic cell downregulation driven by IFN-gamma, as it was already demonstrated in systemic lupus erythematosus [30]. In conclusion, based on the increased IL-18 levels in plasma of our patients, this cytokine seems to play a role in the etiopathogenesis of psoriasis which was already suggested by many authors. Decreased blood plasmacytoid DCs in psoriatic patients might be related to the IL-18 down-regulation of plasmacytoid DC precursor proliferation. IFN-gamma, by exerting its influence on myeloid/plasmacytid ratio, on the one hand could down-regulate myeloid dendritic cells and on the other hand can protect plasmacytoid dendritic cells from apoptosis. Explanation of the exact mechanisms of interactions between IL-18 and DCs in psoriasis requires, however, further studies.
###end p 33
###begin title 34
ACKNOWLEDGMENTS
###end title 34
###begin p 35
The authors thank M. Kowal for the technical support. This work was supported by the Research Grant from the Medical University of Lublin (PW 170/2006).
###end p 35
###begin article-title 36
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis
###end article-title 36
###begin article-title 37
Miejsce IL-18 w chorobach alergicznych
###end article-title 37
###begin article-title 38
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis: preliminary considerations
###end article-title 38
###begin article-title 39
IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family
###end article-title 39
###begin article-title 40
Evidence of IL-18 as a novel angiogenic mediator
###end article-title 40
###begin article-title 41
IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response
###end article-title 41
###begin article-title 42
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Interleukin-18 serum concentration in patients with psoriasis triggered by infection
###end article-title 42
###begin article-title 43
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Interleukin-18 levels in the plasma of psoriatic patients correlate with the extent of skin lesions and the PASI score
###end article-title 43
###begin article-title 44
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Plasma level of interleukin 18 in psoriatic patients during topical treatment
###end article-title 44
###begin article-title 45
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human keratinocytes are major producers of IL-18: predominant expression of the unprocessed form
###end article-title 45
###begin article-title 46
Expression of IL-18 in psoriasis
###end article-title 46
###begin article-title 47
Howie SEM. Psoriatic skin expresses high levels of interleukin-18 (IL-18) and IL-18 receptor (IL-18R)
###end article-title 47
###begin article-title 48
Psoriatic epidermis expresses high levels of interleukin 18 (IL-18), IL-18 receptor mRNA and IL-18
###end article-title 48
###begin article-title 49
Interferon gamma in keratinocytes in psoriasis
###end article-title 49
###begin article-title 50
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human peripheral blood contains two distinct lineages of dendritic cells
###end article-title 50
###begin article-title 51
###xml 20 25 <span type="species:ncbi:9606">human</span>
Characterization of human blood dendritic cell subsets
###end article-title 51
###begin article-title 52
Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions
###end article-title 52
###begin article-title 53
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Compartmental imbalance and aberrant immune function of blood CD123+ (plasmacytoid) and CD11c+ (myeloid) dendritic cells in atopic dermatitis
###end article-title 53
###begin article-title 54
Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases
###end article-title 54
###begin article-title 55
Analysis of associations between peripheral blood dendritic cells, serum cortisol level, quality of life and clinical severity of psoriasis
###end article-title 55
###begin article-title 56
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human dendritic cells express the IL-18R and are chemoattracted to IL-18
###end article-title 56
###begin article-title 57
Interleukin-18 regulates both Th1 and Th2 responses
###end article-title 57
###begin article-title 58
###xml 146 151 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#947;</italic>
Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers - IL-12, IL-18 and IL-23
###end article-title 58
###begin article-title 59
Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu
###end article-title 59
###begin article-title 60
Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression
###end article-title 60
###begin article-title 61
###xml 43 48 43 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
###xml 72 73 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4+ T cells during T helper (Th)1/Th2 differentiation: critical downregulatory role of IL-4
###end article-title 61
###begin article-title 62
Reciprocal control of T helper cell and dendritic cell differentiation
###end article-title 62
###begin article-title 63
###xml 70 75 70 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#945;</italic>
Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production
###end article-title 63
###begin article-title 64
Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus
###end article-title 64
###begin p 65
###xml 278 286 <span type="species:ncbi:9606">patients</span>
(a) Myeloid and plasmacytoid DCs were quantified as the percentages of peripheral blood mononuclear cells, (b) mDCs were defined as BDCA-1 positive and simultaneously CD19 negative cells, (c) pDCs as double BDCA-2 and CD123 positive cells. Correlations between IL-18 and DCs in patients with psoriasis and healthy controls.
###end p 65
###begin p 66
###xml 19 22 <span type="species:ncbi:9606">men</span>
Comparison between men with psoriasis and healthy subjects: (a) percentages myeloid BDCA-1+/CD19- DCs, (b) plasmacytoid BDCA2+/CD123+ DCs, (c) myeloid/plasmacytoid ratio, and (d) blood concentration of IL-18. Results are shown as median values and 25-75 percentiles.
###end p 66
###begin p 67
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Correlations between IL-18 and DCs in patients with psoriasis and healthy controls.
###end p 67
###begin p 68
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Demographic, physical, and behavioural characteristics of patients with psoriasis and healthy controls.
###end p 68
###begin p 69
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 176 177 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Spearman rho correlation coefficients between IL-18 and DCs in patients with psoriasis and healthy controls. Correlations marked by asterisk are statistically significant with P < .05.
###end p 69
###begin p 70
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rho</italic>
###xml 195 196 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Spearman rho correlation coefficients between IL-18, DCs, and clinical characteristics of psoriasis in patients with psoriasis. Correlations marked by asterisk are statistically significant with P < .05.
###end p 70

